PRISM BioLab (206A) · RiskRestated
Revenue Pressure from Healthcare Cost-Containment Measures and Drug Price Cuts
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Market and earnings impact on the pharmaceutical business from drug price revisions, healthcare system changes and pricing policy changesA theme 88 companies write about · 104 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
47 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 88 companies compared. The sentences above are computed from all 88.Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「In recent years, Japan has implemented measures as part of efforts to contain medical expenses, including reductions in the prices of prescription drugs, generally every 2 years, and the promotion of generic drug use.」
Earnings pressure from drug price reductions and the spread of generic drugs, among other factors, was reiterated. - FY2024First statedAnnual report
「In recent years, Japan has implemented measures as part of efforts to contain medical expenses, including reductions in the prices of prescription drugs, generally every 2 years, and the promotion of generic drug use.」
The company identifies as risks the impact on results of drug prices falling below expectations and product demand declining.